BlackSky Technology Misses Q2 Consensus, Sees Strong Contract Win

BlackSky Technology Inc (NYSE: BKSY) reported second-quarter (Q2) 2023 revenue growth of 28% year-over-year to $19.33 million, missing the consensus of $20.55 million.

BlackSky Technology Inc (NYSE:BKSY) reported second-quarter (Q2) 2023 revenue growth of 28% year-over-year to $19.33 million, missing the consensus of $20.55 million.

Imagery & software analytical services revenue grew 51% Y/Y to $15.3 million, and Professional & engineering services revenue was $4 million (-18.4% Y/Y).

EPS loss of 24 cents missed the consensus loss of 12 cents.

Operating losses hovered at around $19.9 million versus $21.7 million a year ago.

Adjusted EBITDA loss was $5.8 million compared to $8.8 million in the prior year. The improvement reflects strong operating leverage achieved through increased high-margin imagery and analytics revenue.

BKSY held cash and equivalents of $59.5 million. 

BlackSky CEO Brian E. O’Toole touted that the company “won” over $35 million in new contracts and renewal agreements since Q2 began. Clients include U.S. and international government agencies.

BlackSky’s total bookings year to date are over $200 million.

FY23 Outlook reaffirmed: BlackSky expects 2023 revenue of $84 million – $96 million (prior $90 million — $96 million) vs consensus $91.62 million.

It reiterated capital expenditures for FY23 of $40 million — $45 million. 

The company remains on track to achieve positive Adjusted EBITDA in Q4 of 2023.

Price Action: BKSY shares are trading lower by 2.72% at $1.79 premarket on the last check Wednesday.

Image:

Total
0
Shares
Related Posts
Read More

Bitcoin, Ethereum, Dogecoin Surge Predictions, BlackRock’s ETF Optimism And More: Top Crypto News This Week

It’s been an eventful week in the world of cryptocurrencies. Analysts are predicting a potential surge in Dogecoin’s value while Bitcoin continues to rally, thanks to increasing interest in Bitcoin Spot ETFs. Additionally, BlackRock is hopeful about the approval of its Bitcoin ETF. Let’s dive into the details. Dogecoin Predicted to Soar

$DOGE

Read More

Vera Therapeutics’ Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst

Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).

VERA